According to a market report by Lucintel, the future of the global oncology drugs market looks promising with opportunities in the blood cancer, breast cancer gastrointestinal cancer, prostate cancer, and respiratory or lung cancer markets. The global oncology drugs market is expected to reach an estimated $411 billion by 2030 at a CAGR of 11% from 2024 to 2030. The major drivers for this market are rising global cancer prevalence fuels demand, innovations in targeted therapies and immunotherapies drive market growth, and higher cancer rates among elderly populations.
In this market, chemotherapy, targeted therapy, immunotherapy, and
hormonal therapy are the major segments of oncology drugs market by type.
Lucintel forecasts that chemotherapy will remain the largest segment over
the forecast period.
Within this market, breast cancer will remain the larger segment.
Download sample by clicking on oncology drugs
market.
North America will remain the largest region over the forecast period.
Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson,
Merck & Co, and AstraZeneca are the major suppliers in the oncology drugs
market.
This unique research report will enable you to make confident business
decisions in this globally competitive marketplace. For a detailed table of
contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get acces of more than 1000 reports at fraction of cast
visit Lucintel’s Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth
through game
changer ideas and robust market & unmet
needs analysis. We are based in Dallas, TX and have
been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in
several publications like the Wall Street Journal, ZACKS, and the Financial
Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1 972.636.5056
Explore Our Latest
Publications
Composites
in the Global Automotive Market
No comments:
Post a Comment